Better vaccine yield
In our case, genetic research primarily pursues the goal of improving vaccine yield per egg used while making egg production sustainable through lower resource use or higher resource efficiency.
The selected animals or their descendants are subsequently “purified for 3 years” according to the requirements of the European Pharmacopoeia, Chapter 5.2.2. or the United States Department of Agriculture Veterinary Services Memorandum 800.65 and crossed in a further generation before the SPF eggs are allowed to be sold as such.
We record all our production data digitally and in detail worldwide. This gives us a detailed view of the performance of the animals in production as well as selected quality parameters of the SPF eggs (such as fertilization rates, shell stability).
In addition, we receive structured feedback from our customers on the results the eggs have yielded in vaccine production or research trials.
Based on the data collected internally and externally, we discuss with the geneticists at Lohmann Breeders what the breeding index for the next generation of SPF genetics should look like.
We repeat this cycle every 2 years so that refreshed genetics are available for production every 2 years as well.
Furthermore, in the SPF area, feed represents a significant risk for the introduction of undesirable pathogens. To minimize this risk, we rely on our own feed mill to supply our SPF stocks in Europe. It is located in the north of Germany and enables us to achieve the best possible feed safety and quality through the selection of raw material quality, thermal treatment, and all associated delivery and distribution procedures. This is also documented by the certifications according to GMP+ B1, HACCP, ISO 9001:2015.
We ensure equally high feed quality and safety for our SPF animals in the U.S. and Brazil through feed mills operated by our sister company at the highest level of hygiene.
In the area of clean egg production, we work with external, local feed mills that are first approved by us through audits and then regularly audited.
Infrastructure and processes
We continuously invest in both the physical and IT infrastructure of our production. This applies to all locations and products and is carried out with the aim of high-quality and efficient production with the best biosecurity and the highest animal welfare standards.
The starting point for any further development is the live data that we continuously generate and evaluate in our production processes. They give us the opportunity to identify and realize potential for improvement in the production process at an early stage. We incorporate our customers' data to ensure a comprehensive assessment of the process chain. Because we are pursuing the common goal of being able to produce more vaccine doses with fewer eggs in the end.